Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple agonist retatrutide and Novo Nordisk’s CagriSema. He reviews Triumph 1 obesity results (up to 25% average weight loss at 80 weeks) and highlights New England Journal of Medicine Phase 3 data showing large reductions in obstructive sleep apnea events in people with and without type 2 diabetes, while noting uncertainty about weight-loss versus nervous-system mechanisms. He also covers TRANSCEND CKD Phase 2B kidney findings: no significant improvement in measured GFR, but favorable secondary markers including reduced urine albumin in a subset. Novo’s post hoc Redefine 1 analyses show strong CagriSema weight loss across pre-, peri-, and post-menopausal women. He discusses Zealand/Roche’s petrelintide Phase 2 results emphasizing low GI discontinuation and argues tolerability matters as much as potency. The episode closes on worsening affordability and coverage, including employers dropping benefits and Pennsylvania Medicaid GLP-1 spending rising to an estimated $1.3B, warning restricted access fuels the gray market.00:00 Big Week in Obesity Drugs00:53 Show Intro and Disclaimers02:03 Sponsor Spotlight VoaFit03:06 Retatrutide Weight Loss Context05:27 Sleep Apnea Phase 3 Results10:23 Beyond Weight Loss Benefits12:14 Kidney Study Nuance16:53 CagriSema Menopause Data19:20 Petrelintide Amylin Update23:33 Top Host Voting Pitch ( otplinks.com )25:29 Access and Coverage Crisis27:42 Medicaid Costs and Gray Market31:21 Wrap Up and Schedule